Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App





US National COVID-19 Diagnostic Supply Registry Launched to Provide Updates on Molecular, Antigen and Serology Tests Shipments

By LabMedica International staff writers
Posted on 23 Jul 2020
A new US national testing registry has been launched to aid in the fight against COVID-19 and has released the first data set that shows more than 65 million tests have been shipped nationwide since the beginning of the pandemic.

This comprehensive, national COVID-19 diagnostic supply registry has been created by the Advanced Medical Technology Association (AdvaMed Washington, D.C., USA) to help state and federal governments in their pandemic responses. More...
The national registry is being launched in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. AdvaMed has been working closely with the White House, HHS, FDA, FEMA and other key government agencies to ensure the continued supply of diagnostics tests, as well as other vital medical equipment such as PPE and ventilators, in the fight against the COVID-19 pandemic.

AdvaMed’s registry will compile information from diagnostic companies along with publicly available data on daily tests performed to create a centralized and standardized COVID-19 diagnostic supply registry. It will provide weekly state- and national-level updates on the number of molecular, antigen, and serology (antibody) tests shipped in the US. AdvaMed’s registry will help streamline communications and data sharing between diagnostic companies and federal and state governments as well as standardize test supply reporting. It will also facilitate collaboration with laboratories and other public health stakeholders to optimize access to all platforms of COVID-19 testing so that any potential shortages are identified and addressed quickly. The registry’s first publicly released dataset shows that since the beginning of the pandemic, more than 65 million tests have been manufactured and shipped nationwide, with test shipments now topping 800,000 daily.

“It is absolutely vital to our nation’s health and economic recovery that we have sufficient supplies to test everyone who needs it, and, just as important, to know where these supplies are so we can get them where they are most needed,” said Scott Whitaker, president and CEO of AdvaMed. “This national registry will be a crucial tool for federal and state authorities as they work to protect both patients and health care providers and move to reopen the U.S. economy.”

“We hope this registry serves as a key tool in our fight against COVID-19. We stand ready to partner with all providers, laboratories and other key stakeholders in the testing ecosystem to collaborate with the federal and state governments to coordinate efforts to support patient care and public health. Further, we stand ready to work with our partners in the federal government on any policies that would allow this registry to better serve patients and providers in need,” Whitaker concluded.

Related Links:
Advanced Medical Technology Association (AdvaMed)


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.